• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Learn Why The Bull Case For Humana (HUM) Could Change Following Prior Authorization Expansion

    Simply Wall St·11/05/2026 02:52:43
    Listen to the news
    • Humana and athenahealth expanded electronic prior authorization across athenahealth’s network of more than 180,000 clinicians, integrating documentation, submission and decisions into athenaOne using FHIR-based standards. Separately, Humana’s board declared a cash dividend of $0.885 per share payable in January 2027.
    • The rollout showed early signs of lower administrative friction, with over 6,000 providers processing nearly 35,000 electronic prior authorization transactions in September and more than 70% completed without extra staff input. This aligns with Humana’s cost and workflow priorities in Medicare Advantage.
    • The next area of focus is how Humana’s investment narrative could be influenced by this scaled electronic prior authorization initiative with athenahealth.

    Scan beyond Humana and see how other payers are trying to streamline care delivery by reviewing our curated list of 38 healthcare AI stocks.

    Humana Investment Narrative Recap

    To own Humana, you need to believe its Medicare Advantage margin restoration plan and cost work can steadily improve a business that currently runs on thin 0.9% net margins and has seen earnings decline over the past year. The short term story still hinges on executing plan exits, value based care, and operating efficiency while managing medical costs.

    The expanded athenahealth prior authorization rollout feeds directly into that operational agenda by trimming friction for providers and potentially supporting Humana’s 3% pretax Medicare Advantage margin goal for 2028. The biggest near term risk remains regulatory pressure on Medicare Advantage coding and reimbursement, which this tech partnership does not materially change.

    The recent dividend declaration of US$0.885 per share, payable in January 2027, is the other relevant signal around Humana right now. It points to a board comfortable returning cash while the firm pursues its multiyear efficiency and margin plan, even after a year where earnings trends have been pressured and one off losses weighed on reported results.

    For you as an investor, that payout sits alongside the athenahealth expansion as a reminder that the thesis is still execution heavy. Margin restoration, plan pruning around roughly 600,000 Medicare Advantage members, and growth in CenterWell and value based models remain the real catalysts, while coding scrutiny, Stars outcomes and lower than expected member retention remain key risks to watch.

    Humana’s current analyst script points to revenues of US$187.5b and earnings of US$4.1b by 2029, based on 8.8% yearly revenue growth and an earnings increase of about US$2.8b from roughly US$1.3b today.

    Uncover why Humana's fair value indicates an 11% potential upside to its current price before that discount narrows.

    NYSE:HUM 1-Year Stock Price Chart
    NYSE:HUM 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view says the real swing factor for Humana is drug trend rather than tech partnerships. The most cautious analysts were only modeling revenue of about US$173.1b and earnings near US$3.9b by 2029, before this athenahealth news. That more muted setup could shift if electronic prior authorization materially reshapes cost assumptions.

    Explore 5 other Humana fair value estimates, including one that suggests as much as 49% downside from the current price.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Ideas Beyond Humana?

    Once you have a view on Humana, it can help to compare it with other opportunities that fit different risk and return profiles. The Simply Wall St Screener can surface stocks that match specific traits so you can build a watchlist that suits your own approach, rather than relying on one headline story.